Recently extracorporeal shockwave lithotripsy (ESWL) has been introduced as a nonoperative treatment for gallstone disease. Except 
Gallstone disease represents an important health care problem in the western world. The estimated prevalence of gallstones is about 10% to 15% and increases with advancing age.2 Although many gallstones do not cause symptoms and need not be treated,3-5 gallstone disease is a major cause of hospitalization for surgical treatment. In the United States annually more than $1 billion is spent on treatment of gallstones, mainly for the 500,000 cholecystectomies performed each year. 6 Since Langenbuch performed the first cholecystectomy in Berlin in 1882,7 operative removal ofthe gallbladder has become the standard therapy for patients with symptomatic gallbladder stones. Cholecystectomy has an overall mortality rate of 0.6% to 1.3%, increasing from 0.2% in patients younger than 70 years to 5% in patients older than 70 years.8-1" A safe and effective treatment for many patients, the mor-available for both cholecystolithiasis and choledocholithiasis. Although still in its infancy, ESWL of gallstones is one of the most promising noninvasive treatment modalities for cholelithiasis. In this review article we will discuss the possibilities and the limitations of ESWL for the management of gallstone disease.
Principle of Shockwave Application
The basic physical principles have been described in detail elsewhere,'4"15 and presently only the essential clinical facts have been compiled. Shockwaves cause high pressure amplitudes to increase within nanoseconds and to respond to the known physical laws of acoustics. If water is used as a transmission medium, focused shockwaves spread through the body evenly without severely damaging the tissues because the acoustical impedance of most body tissues is close to that of water. At its focus point, the wave impact against the stone liberates shortterm high-energy mechanical stresses because of the abrupt change in acoustical impedance. This causes tearand-shear forces, which, together with the formation of cavitation bubbles in the surrounding medium on the surface of the stone, eventually lead to the disintegration of the stone.'6"17 1 The original waterbath lithotriptor developed by Dor implanted gallbladder stones in dogs also resulted in pulmonary damage (alveolar hemorrhage) involving areas just above the diaphragm in one third of the animals;29 no animal died, and no hemoptysis was noted after shockwave application (Delius, written personal communication, 1988). These serious side effects are dependent on the shockwave pressure field. They do not occur when the lungs are more than 4 cm removed from the shockwave axis. 30 Other investigators have observed no changes or lesions in the right lung only in dogs autopsied one day after ESWL; no changes were observed in animals killed 14 days after treatment.26'3' The differences in outcome of shockwave application can be explained by differences in shockwave pressure distribution in the acoustic fields generated by the various lithotriptors.
Differences in the physical characteristics of shockwave pulses generated by differing lithotriptors are also responsible for the variation in results of in vitro fragmentation studies ofhuman gallstones.32 Soft cholesterol stones with a low density, as assessed by computed tomography, required more discharges to fragment the stone than those with a high pigment and calcium content.33 '34 On the other hand, other studies revealed successful fragmentation regardless of the chemical composition or the calcium content of the stone and suggest that ESWL may be applied to all types of gallstones. The effectiveness of this therapy will then only be limited by the total stone burden and the time required to complete stone fragmentation. This corresponds well with the observation that the number of shockwaves required to bring about fragmentation of human gallstones in vitro correlated closely with the number, volume, weight, and diameter of the stones.' Clinical Application of ESWL for Gallstones Gallbladder Stones
The first successful ESWL treatment of patients with gallstones was reported by Sauerbruch and coworkers in 1986.39 They treated nine patients with functioning gallbladders containing 1 to 3 symptomatic radiolucent stones that were not larger than 25 mm in diameter. All stones were disintegrated into sludge or fragments. At present more than 1000 patients with gallbladder stones, most of them in Germany, have undergone ESWL on different systems ( Table 2 ).The selection of patients is usually determined according to the inclusion and exclusion criteria of the Munich group (Table 3) .
Because 
